Cholinergic deficiency involved in vascular dementia: Possible mechanism and strategy of treatment

Acta Pharmacologica Sinica

Volumn 30, Issue 7, 2009, Pages 879-888

  Wang, Juan ^a   Zhang, Hai Yan ^a   Tang, Xi Can ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Acetylcholinesterase inhibitor; Cholinergic deficit; Inflammation; Vascular dementia

Indexed keywords

4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; CHOLINE ALFOSCERATE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CITICOLINE; DONEPEZIL; GALANTAMINE; HUPERZINE A; LIGUSTILIDE; MECAMYLAMINE; METHANESULFONYL FLUORIDE; NEFIRACETAM; NICOTINE; NICOTINIC AGENT; PHOSPHATIDYLCHOLINE; RIVASTIGMINE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; COGNITIVE DEFECT; CYTOKINE RELEASE; DEGENERATIVE DISEASE; ENERGY METABOLISM; HUMAN; INFLAMMATION; MULTIINFARCT DEMENTIA; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; VAGUS NERVE;

ACETYLCHOLINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; DISEASE MODELS, ANIMAL; GALANTAMINE; HUMANS; INDANS; INFLAMMATION; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; RECEPTORS, CHOLINERGIC; SESQUITERPENES; SIGNAL TRANSDUCTION;

EID: 67651166807     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2009.82     Document Type: Review

References (134)

1. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008; 7: 812-26.
2. Sloane PD, Zimmerman S, Suchindran C, Reed P, Wang L, Boustani M, et al. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 2002; 23: 213-31.
3. Sorrentino G, Migliaccio R, Bonavita V. Treatment of vascular dementia: the route of prevention. Eur Neurol 2008; 60: 217-23.
4. Bonita R. Epidemiology of stroke. Lancet 1992; 339: 342-4.
5. Kumaran D, Udayabanu M, Kumar M, Aneja R, Katyal A. Involvement of angiotensin converting enzyme in cerebral hypoperfusion induced anterograde memory impairment and cholinergic dysfunction in rats. Neuroscience 2008; 155: 626-39.
6. Kuang X, Du JR, Liu YX, Zhang GY, Peng HY. Postischemic administra tion of Z-Ligustilide ameliorates cognitive dysfunction and brain damage induced by permanent forebrain ischemia in rats. Pharmacol Biochem Behav 2008; 88: 213-21.
7. Pavlov VA, Tracey KJ. The cholinergic anti-inflammatory pathway. Brain Behav Immun 2005; 19: 493-9.
8. Jellinger KA. The pathology of ischemic-vascular dementia: An update. J Neurol Sci 2002; 203-204: 153-7.
9. Jellinger KA. The pathology of "vascular dementia": a critical update. J Alzheimers Dis 2008; 14: 107-23.
10. Roman GC. Cholinergic dysfunction in vascular dementia. Curr Psychiatry Rep 2005; 7: 18-26.
11. Roman GC, Kalaria RN. Vascular determinants of cholinergic defcits in Alzheimer disease and vascular dementia. Neurobiol Aging 2006; 27: 1769-85.
12. Ni JW, Matsumoto K, Li HB, Murakami Y, Watanabe H. Neuronal damage and decrease of central acetylcholine level following permanent occlusion of bilateral common carotid arteries in rat. Brain Res 1995; 673: 290-6.
13. Tanaka K, Ogawa N, Asanuma M, Kondo Y, Nomura M. Relationship between cholinergic dysfunction and discrimination learning disabilities in Wistar rats following chronic cerebral hypoperfusion. Brain Res 1996; 729: 55-65.
14. Zhao Q, Murakami Y, Tohda M, Obi R, Shimada Y, Matsumoto K. Chotosan, a kampo formula, ameliorates chronic cerebral hypoperfusion-induced deficits in object recognition behaviors and central cholinergic systems in mice. J Pharmacol Sci 2007; 103: 360-73.
15. Zhang LL, Wang JZ, Liu SW, Chen ME. Changes of somatostatin and acetylcholine contents in vascular dementia rats. Acta Acad Med Milit Tert 2004; 26: 714-6. In Chinese (with English abstract).
16. Borlongan CV, Sumaya IC, Moss DE. Methanesulfonyl fluoride, an acetylcholinesterase inhibitor, attenuates simple learning and memory defcits in ischemic rats. Brain Res 2005; 1038: 50-8.
17. Francis A, Pulsinelli W. The response of GABAergic and cholinergic neurons to transient cerebral ischemia. Brain Res 1982; 243: 271-8.
18. Nyberg P, Waller S. Age-dependent vulnerability of brain choline acetyltransferase activity to transient cerebral ischemia in rats. Stroke 1989; 20: 495-500.
19. Naritomi H. Experimental basis of multi-infarct dementia: memory impairments in rodent models of ischemia. Alzheimer Dis Assoc Disord 1991; 5: 103-11.
20. Togashi H, Matsumoto M, Yoshioka M, Hirokami M, Minami M, Saito H. Neurochemical profles in cerebrospinal fuid of stroke-prone spontaneously hypertensive rats. Neurosci Lett 1994; 166: 117-20.
21. Kimura S, Saito H, Minami M, Togashi H, Nakamura N, Nemoto M, et al. Pathogenesis of vascular dementia in stroke-prone spontaneously hypertensive rats. Toxicology 2000; 153: 167-78.
22. Kalaria R. Similarities between Alzheimer's disease and vascular dementia. J Neurol Sci 2002; 203-204: 29-34.
23. Waller SB, Ball MJ, Reynolds MA, London ED. Muscarinic binding and choline acetyltransferase in postmortem brains of demented patients. Can J Neurol Sci 1986; 13: 528-32.
24. Gottfries CG, Blennow K, Karlsson I, Wallin A. The neurochemistry of vascular dementia. Dementia 1994; 5: 163-7.
25. Tohgi H, Abe T, Kimura M, Saheki M, Takahashi S. Cerebrospinal fuid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia. J Neural Transm 1996; 103: 1211-20.
26. Wallin A, Sjogren M, Blennow K, Davidsson P. Decreased cerebrospinal fuid acetylcholinesterase in patients with subcortical ischemic vascular dementia. Dement Geriatr Cogn Disord 2003; 16: 200-7.
27. Mann DM, Yates PO, Marcyniuk B. The nucleus basalis of Meynert in multi-infarct (vascular) dementia. Acta Neuropathol 1986; 71: 332-7.
28. Keverne JS, Low WC, Ziabreva I, Court JA, Oakley AE, Kalaria RN. Cholinergic neuronal defcits in CADASIL. Stroke 2007; 38: 188-91.
29. Mesulam M, Siddique T, Cohen B. Cholinergic denervation in a pure multi-infarct state: observations on CADASIL. Neurology 2003; 60: 1183-5.
30. Court J, Perry E, Kalaria R. Neurotransmitter control of the cerebral vasculature and abnormalities in vascular dementia. In: Erkinjuntti T, Gauthier S, editors. Vascular cognitive impairment. Martin Dunitz, London; 2002. p 167-85.
31. Nizri E, Hamra-Amitay Y, Sicsic C, Lavon I, Brenner T. Anti-infammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 2006; 50: 540-7.
32. Wang Q, Tang XN, Yenari MA. The infammatory response in stroke. J Neuroimmunol 2007; 184: 53-68.
33. Barone FC, Feuerstein GZ. Infammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19: 819-34.
34. Liu R, Wen Y, Perez E, Wang X, Day AL, Simpkins JW, et al. 17beta-Estradiol attenuates blood-brain barrier disruption induced by cerebral ischemia-reperfusion injury in female rats. Brain Res 2005; 1060: 55-61.
35. Pan J, Konstas AA, Bateman B, Ortolano GA, Pile-Spellman J. Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies. Neuroradiology 2007; 49: 93-102.
36. Mehta SL, Manhas N, Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007; 54: 34-66.
37. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic infammatory response to endotoxin. Nature 2000; 405: 458-62.
38. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nico tinic acetylcholine receptor alpha7 subunit is an essential regulator of infammation. Nature 2003; 421: 384-8.
39. Conejero-Goldberg C, Davies P, Ulloa L. Alpha7 nicotinic acetylcholine receptor: a link between infammation and neuro degeneration. Neurosci Biobehav Rev 2008; 32: 693-706.
40. Pavlov VA, Tracey KJ. Controlling infammation: the cholinergic antiinfammatory pathway. Biochem Soc Trans 2006; 34: 1037-40.
41. Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease. Dement Geriatr Cogn Disord 2000; 11 Suppl 1: 11-8.
42. Murakami Y, Zhao Q, Harada K, Tohda M, Watanabe H, Matsumoto K. Choto-san, a Kampo formula, improves chronic cerebral hypo- perfusion-induced spatial learning deficit via stimulation of muscarinic M1 receptor. Pharmacol Biochem Behav 2005; 81: 616-25.
43. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, rando mized, placebo-controlled trial. Clin Ther 2003; 25: 178-93.
44. Adibhatla RM, Hatcher JF. Cytidine 5'-diphosphocholine (CDP-choline) in stroke and other CNS disorders. Neurochem Res 2005; 30: 15-23.
45. Kavirajan H, Schneider LS. Effcacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a metaanalysis of randomised controlled trials. Lancet Neurol 2007; 6: 782-92.
46. Dichgans M, Markus HS, Salloway S, Verkkoniemi A, Moline M, Wang Q, et al. Donepezil in patients with subcortical vascular cognitive impair ment: a randomised double-blind trial in CADASIL. Lancet Neurol 2008; 7: 310-8.
47. Kim DH, Yoon BH, Kim YW, Lee S, Shin BY, Jung JW, et al. The seed extract of Cassia obtusifolia ameliorates learning and memory impair ments induced by scopolamine or transient cerebral hypoperfu sion in mice. J Pharmacol Sci 2007; 105: 82-93.
48. Wang ZF, Wang J, Zhang HY, Tang XC. Huperzine A exhibits antiinfammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. J Neurochem 2008; 106: 1594-603.
49. Wecker L, Schmidt DE. Central cholinergic function: relationship to choline administration. Life Sci 1979; 25: 375-84.
50. Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J Neurol Sci 2007; 257: 264-9.
51. Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev 2003; 3: CD001015.
52. Domino EF, Mathews BN, Tait SK, Ortiz A. Effects of oral phosphatidyl choline on mouse brain choline and acetylcholine. Arch Int Pharmacodyn Ther 1983; 265: 49-54.
53. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2005; 2: CD000269.
54. 14C]-L-alpha-glyceryl phosphorylcholine. Eur J Drug Metab Pharmacokinet 1993; 18: 173-80.
55. Amenta F, Franch F, Ricci A, Vega JA. Cholinergic neurotransmission in the hippocampus of aged rats: infuence of L-alpha-glyceryl phosphorylcholine treatment. Ann N Y Acad Sci 1993; 695: 311-3.
56. Tomassoni D, Avola R, Mignini F, Parnetti L, Amenta F. Effect of treatment with choline alphoscerate on hippocampus microanatomy and glial reaction in spontaneously hypertensive rats. Brain Res 2006; 1120: 183-90.
57. Parnetti L, Amenta F, Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev 2001; 122: 2041-55.
58. Bontempi B, Whelan KT, Risbrough VB, Lloyd GK, Menzaghi F. Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuro psychopharmacology 2003; 28: 1235-46.
59. Fukatsu T, Miyake-Takagi K, Nagakura A, Omino K, Okuyama N, Ando T, et al. Effects of nefiracetam on spatial memory function and acetylcholine and GABA metabolism in microsphere-embolized rats. Eur J Pharmacol 2002; 453: 59-67.
60. Crespi F. Nefracetam. Daiichi Seiyaku. Curr Opin Investig Drugs 2002; 3: 788-93.
61. Zhao X, Kuryatov A, Lindstrom JM, Yeh JZ, Narahashi T. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons. Mol Pharmacol 2001; 59: 674-83.
62. Wonnacott S, Marks MJ. Nicotine: not just for cigarettes anymore. Drug Discov Today 1999; 4: 490-492.
63. Maelicke A, Albuquerque E. New approach to drug therapy in Alzheimer's dementia. Drug Discov Today 1996; 1: 53-9.
64. Shimada Y, Yang Q, Yokoyama K, Goto H, Kasahara Y, Sekiya N, et al. Choto-san prevents occurrence of stroke and prolongs life span in stroke-prone spontaneously hypertensive rats. Am J Chin Med 2003; 31: 79-85.
65. Terasawa K, Shimada Y, Kita S. Choto-san in the treatment of vascular dementia: a double-blind, placebo-controlled study. Phytomedicine 1997; 4: 15-22.
66. Shimada Y, Terasawa K, Yamamoto T. A well-controlled study of Choto-san and placebo in the treatment of vascular dementia. J Tradit Med 1994; 11: 246-55.
67. Thal LJ, Forrest M, Loft H, Mengel H. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group. Neurology 2000; 54: 421-6.
68. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD005593.
69. Farlow MR. Use of antidementia agents in vascular dementia: beyond Alzheimer disease. Mayo Clin Proc 2006; 81: 1350-8.
70. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. An open-label pilot study comparing rivastigmine and low-dose aspirin for the treatment of symptoms specifc to patients with subcorticl vascular dementia. Curr Ther Res 2002; 63: 443-58.
71. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Effcacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-30.
72. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV. An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003; 25: 1765-82.
73. Yin FM, Du YY, Wang LE. Huperzine A interventions on vascular dementia. Modern Rehabilit 2001; 5: 74-5. In Chinese.
74. Wang YE, Yue DX, Tang XC. Anticholinesterase activity of huperzine A. Acta Pharmacol Sin 1986; 7: 110-3. In Chinese (with English abstract).
75. Zhang ZX, Wang XD, Chen QT, Shu L, Wang JZ, Shan GL. Clinical effcacy and safety of huperzine A in treatment of mild to moderate Alzheimer's disease, a placebo-controlled, doube-blind, randomized trial. Natl Med J China 2002; 82: 941-4. In Chinese (with English abstract).
76. Wang RP, Zhao ZK, Hu LL. Effect of huperzine A on cognitive function and quality of life in vascular dementia: 36 cases for 6 months follow up study. Chin J Clin Rehabilit 2004; 8: 3892. In Chinese.
77. Zhang RW, Tang XC, Han YY, Sang GW, Zhang YD, Ma YX, et al. Drug evaluation of huperzine A in the treatment of senile memory disorders. Acta Pharmacol Sin 1991; 12: 250-2. In Chinese (with English abstract).
78. Sun CY, Chen XY. A self-control study of huperzine A on memory deficits in patients with multiple infarctions. Henan Yi Yao Xin Xi 1998; 6: 31-2. In Chinese.
79. Wang YQ. Treatment of tablet huperzine A on 17 patients with vascular dementia. China Pharm 2000; 9: 32. In Chinese.
80. Zhong ZG, Liang KZ. Clinical observation of huperzine A on 29 patients with vascular dementia. J Hainan Med Coll 2004; 10: 251-2. In Chinese.
81. Chang JJ. Huperzine A vs pyritinol in treating dementia from mulltiple infarctions. New Drugs Clin Remedies 1997; 16: 333-4. In Chinese (with English abstract).
82. Wang LM, Han YF, Tang XC. Huperzine A improves cognitive defcits caused by chronic cerebral hypoperfusion in rats. Eur J Pharmacol 2000; 398: 65-72.
83. Zhou J, Zhang HY, Tang XC. Huperzine A attenuates cognitive defcits and hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci Lett 2001; 313: 137-40.
84. Wang LS, Zhou J, Shao XM, Tang XC. Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxiaischemia. Brain Res 2002; 949: 162-70.
85. Wang ZF, Tang LL, Yan H, Wang YJ, Tang XC. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol Biochem Behav 2006; 83: 603-11.
86. Bona E, Andersson AL, Blomgren K, Gilland E, Puka-Sundvall M, Gustafson K, et al. Chemokine and infammatory cell response to hypoxia-ischemia in immature rats. Pediatr Res 1999; 45: 500-9.
87. Hedtjarn M, Mallard C, Hagberg H. Infammatory gene profling in the developing mouse brain after hypoxia-ischemia. J Cereb Blood Flow Metab 2004; 24: 1333-51.
88. Wang ZF, Tang XC. Huperzine A protects C6 rat glioma cells against oxygen-glucose deprivation-induced injury. FEBS Lett 2007; 581: 596-602.
89. Nurmi A, Lindsberg PJ, Koistinaho M, Zhang W, Juettler E, Karjalainen-Lindsberg ML, et al. Nuclear factor-kappaB contributes to infarction after permanent focal ischemia. Stroke 2004; 35: 987-91.
90. Zheng CY, Zhang HY, Tang XC. Huperzine A attenuates mitochondrial dysfunction after middle cerebral artery occlusion in rats. J Neurosci Res 2008; 86: 2432-40.
91. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006; 27: 1-26.
92. Pratt RD, Perdomo CA. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefts. Ann N Y Acad Sci 2002; 977: 513-22.
93. Mendez MF, Younesi FL, Perryman KM. Use of donepezil for vascular dementia: preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999; 11: 268-70.
94. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil in vascular dementia: a randomized, placebocontrolled study. Neurology 2003; 61: 479-86.
95. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database Syst Rev 2004; 1: CD004395.
96. Fujiki M, Kobayashi H, Uchida S, Inoue R, Ishii K. Neuroprotective effect of donepezil, a nicotinic acetylcholine-receptor activator, on cerebral infarction in rats. Brain Res 2005; 1043: 236-41.
97. Fujiki M, Kubo T, Kamida T, Sugita K, Hikawa T, Abe T, et al. Neuro pro tec tive and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury. J Clin Neurosci 2008; 15: 791-6.
98. Takada-Takatori Y, Kume T, Ohgi Y, Izumi Y, Niidome T, Fujii T, et al. Mechanism of neuroprotection by donepezil pretreatment in rat cortical neurons chronically treated with donepezil. J Neurosci Res 2008; 86: 3575-83.
99. Hiranita T, Nawata Y, Sakimura K, Anggadiredja K, Yamamoto T. Suppression of methamphetamine-seeking behavior by nicotinic agonists. Proc Natl Acad Sci U S A 2006; 103: 8523-7.
100. Takada-Takatori Y, Kume T, Ohgi Y, Fujii T, Niidome T, Sugimoto H, et al. Mechanisms of alpha7-nicotinic receptor up-regulation and sensitization to donepezil induced by chronic donepezil treatment. Eur J Pharmacol 2008; 590: 150-6.
101. Tyagi E, Agrawal R, Nath C, Shukla R. Effect of anti-dementia drugs on LPS induced neuroinflammation in mice. Life Sci 2007; 80: 1977-83.
102. Reale M, Iarlori C, Gambi F, Feliciani C, Isabella L, Gambi D. The acetylcholinesterase inhibitor, donepezil, regulates a Th2 bias in Alzheimer's disease patients. Neuropharmacology 2006; 50: 606-13.
103. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 2000; 22: 609-13.
104. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: a comparison trial on effcacy and tolerability for 12 months follow-up. Eur J Neurol 2001; 8: 361-2.
105. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002; 203-204: 141-6.
106. Kumar V, Anand R, Messina J, Hartman R, Veach J. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors. Eur J Neurol 2000; 7: 159-69.
107. Moretti R, Torre P, Antonello RM, Cazzato G, Pizzolato G. Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia. Am J Alzheimers Dis Other Demen 2008; 23: 167-76.
108. Tanaka K, Ogawa N, Mizukawa K, Asanuma M, Kondo Y, Nishibayashi S, et al. Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia. Neurochem Res 1994; 19: 117-22.
109. Tanaka K, Ogawa N, Asanuma M, Hirata H, Kondo Y, Nakayama N, et al. Effects of the acetylcholinesterase inhibitor ENA-713 on ischemia-induced changes in acetylcholine and aromatic amine levels in the gerbil brain. Arch Int Pharmacodyn Ther 1993; 323: 85-96.
110. Chen Y, Shohami E, Bass R, Weinstock M. Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat. Brain Res 1998; 784: 18-24.
111. Tanaka K, Mizukawa K, Ogawa N, Mori A. Post-ischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus. Neurochem Res 1995; 20: 663-7.
112. Nizri E, Irony-Tur-Sinai M, Faranesh N, Lavon I, Lavi E, Weinstock M, et al. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J Neuroimmunol 2008; 203: 12-22.
113. Woodruff-Pak DS, Lander C, Geerts H. Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 2002; 8: 405-26.
114. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-90.
115. Craig D, Birks J. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006; CD004746.
116. Iliev AI, Traykov VB, Mantchev GT, Stoykov I, Prodanov D, Yakimova KS, et al. A post-ischaemic single administration of galanthamine, a cholinesterase inhibitor, improves learning ability in rats. J Pharm Pharmacol 2000; 52: 1151-6.
117. Ji X, Li C, Lu Y, Chen Y, Guo L. Post-ischemic continuous administration of galantamine attenuates cognitive defcits and hippocampal neurons loss after transient global ischemia in gerbils. Neurosci Lett 2007; 416: 92-5.
118. Lorrio S, Sobrado M, Arias E, Roda JM, Garcia AG, Lopez MG. Galanta mine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J Pharmacol Exp Ther 2007; 322: 591-9.
119. Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, et al. Galantamine and nicotine have a synergistic effect on inhibition of microglial activation induced by HIV-1 gp120. Brain Res Bull 2004; 64: 165-70.
120. Santos MD, Alkondon M, Pereira EF, Aracava Y, Eisenberg HM, Maelicke A, et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol Pharmacol 2002; 61: 1222-34.
121. 2+ signals and neurotransmitter release. Mol Pharmacol 2003; 64: 1217-26.
122. Woodruff-Pak DS, Vogel RW 3rd, Wenk GL. Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase, and nicotinic acetylcholine receptors. Neuro science 2003; 117: 439-47.
123. Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-infammatory pathway. Brain Behav Immun 2009; 23: 41-5.
124. Moss DE, Berlanga P, Hagan MM, Sandoval H, Ishida C. Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1999; 13: 20-5.
125. Kuang X, Yao Y, Du JR, Liu YX, Wang CY, Qian ZM. Neuroprotective role of Z-ligustilide against forebrain ischemic injury in ICR mice. Brain Res 2006; 1102: 145-53.
126. Peng HY, Du JR, Zhang GY, Kuang X, Liu YX, Qian ZM, et al. Neuroprotective effect of Z-ligustilide against permanent focal ischemic damage in rats. Biol Pharm Bull 2007; 30: 309-12.
127. Zhou J, Fu Y, Tang XC. Huperzine A and donepezil protect rat pheochromo cytoma cells against oxygen-glucose deprivation. Neurosci Lett 2001; 306: 53-6.
128. Nobili F, Vitali P, Canfora M, Girtler N, De Leo C, Mariani G, et al. Effects of long-term donepezil therapy on rCBF of Alzheimer's patients. Clin Neurophysiol 2002; 113: 1241-8.
129. Lojkowska W, Ryglewicz D, Jedrzejczak T, Minc S, Jakubowska T, Jarosz H, et al. The effect of cholinesterase inhibitors on the regional blood fow in patients with Alzheimer's disease and vascular dementia. J Neurol Sci 2003; 216: 119-26.
130. Ved HS, Koenig ML, Dave JR, Doctor BP. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport 1997; 8: 963-8.
131. Li W, Pi R, Chan HH, Fu H, Lee NT, Tsang HW, Pu Y, et al. Novel dimeric acetyl cholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors. J Biol Chem 2005; 280: 18179-88.
132. Akasofu S, Kimura M, Kosasa T, Sawada K, Ogura H. Study of neuroprotection of donepezil, a therapy for Alzheimer's disease. Chem Biol Interact 2008; 175: 222-6.
133. Ezoulin MJ, Dong CZ, Liu Z, Li J, Chen HZ, Heymans F, et al. Study of PMS777, a new type of acetylcholinesterase inhibitor, in human HepG2 cells. Comparison with tacrine and galanthamine on oxidative stress and mitochondrial impairment. Toxicol In Vitro 2006; 20: 824-31.
134. Casademont J, Miro O, Rodriguez-Santiago B, Viedma P, Blesa R, Cardellach F. Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease. J Neurol Sci 2003; 206: 23-6.